Vanguard Amends Ionis Pharma Stake, Maintains Passive Ownership

TL;DR

**Vanguard still owns a big chunk of Ionis Pharma, but they're just holding, not shaking things up.**

AI Summary

The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, indicating its ownership of Ionis Pharmaceuticals Inc. common stock as of December 29, 2023. This is the 12th amendment to their filing, showing their continued significant, though passive, stake in the company. For investors, this means a large institutional holder like Vanguard maintains confidence in Ionis, which can be a positive signal, but it doesn't suggest any active management changes or new strategic moves from Vanguard's side.

Why It Matters

This filing confirms Vanguard's ongoing substantial, yet passive, investment in Ionis Pharmaceuticals, signaling continued institutional confidence without any intent to influence company management.

Risk Assessment

Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate risks or changes to the company's operations or stock price.

Analyst Insight

A smart investor would note Vanguard's continued passive ownership as a sign of long-term institutional interest in Ionis Pharmaceuticals, but understand that this filing doesn't signal any new strategic developments or immediate catalysts for the stock.

Key Numbers

• 12 — Amendment Number (This is the 12th amendment to Vanguard's Schedule 13G filing for Ionis Pharmaceuticals Inc.)
• 462222100 — CUSIP Number (Identifies Ionis Pharmaceuticals Inc. Common Stock.)
• 23-1945930 — IRS Identification Number (Identifies The Vanguard Group.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Ionis Pharmaceuticals Inc. (company) — issuer of the common stock
• December 29, 2023 (date) — date of event requiring the filing
• February 13, 2024 (date) — filing date of the SC 13G/A
• Pennsylvania (company) — place of organization for The Vanguard Group

FAQ

Filing Documents

• tv01223-ionispharmaceuticals.htm (SC 13G/A) — 11KB
• 0001104659-24-021229.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Ionis Pharmaceuticals Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 2855 Gazelle Court Carlsbad, CA 92010

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 462222100

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR